Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 27;5(8):2272-2278.
doi: 10.1182/bloodadvances.2020003976.

Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients

Marissa Li  1 , Moritz Binder  2 , Terra Lasho  2 , Alejandro Ferrer  2 , Naseema Gangat  2 , Aref Al-Kali  2 , Abhishek Mangaonkar  2 , Michelle Elliott  2 , Mark Litzow  2 , William Hogan  2 , Animesh Pardanani  2 , Alexandra Wolanskyj-Spinner  2 , Matthew Howard  3 , Rebecca L King  3 , Mithun Shah  2 , Hassan Alkhateeb  2 , Kebede Begna  2 , Ayalew Tefferi  2 , Christy Finke  2 , Jennifer Oliveira  3 , Rhett Ketterling  3 , Horatiu Olteanu  3 , Mrinal M Patnaik  2
Affiliations

Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients

Marissa Li et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Molecular characteristics and survival outcomes in patients with clonal cytopenias of undetermined significance, lower-risk myelodysplastic syndromes, and lower-risk chronic myelomonocytic leukemia. (A) Split bean plot demonstrating the 6 most common mutations in both CCUS and LR-MDS and their respective VAFs. (B) Bar graph of CCUS and LR-MDS demonstrating the 10 most frequent mutations in all 188 patients and the percentage of patients with that mutation. (C) Kaplan-Meier OS estimate in CCUS and LR-MDS patients, censored at 10 years of follow-up. (D) Kaplan-Meier leukemia-free survival estimate in CCUS, LR-MDS, and LR-CMML patients, censored at 10 years of follow-up. (E) Distribution of survival and progression outcomes in LR-MDS, LR-CMML, and CCUS patients.
See this image and copyright information in PMC

References

    1. Malcovati L, Gallì A, Travaglino E, et al. . Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129(25):3371-3378. - PMC - PubMed
    1. Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358-1374. - PubMed
    1. Gondek LP, DeZern AE. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematol. 2020;7(1):e73-e81. - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463]. Blood. 2016;127(20):2391-2405. - PubMed
    1. Mangaonkar AA, Ferrer A, Pinto E Vairo F, et al. . Clinical applications and utility of a precision medicine approach for patients with unexplained cytopenias. Mayo Clin Proc. 2019;94(9):1753-1768. - PMC - PubMed

Publication types